Biotech | April 09, 2026
Gilead to acquire Tubulis for up to $5 billion to strengthen its oncology portfolio
The acquisition complements Gilead’s existing oncology expertise and development infrastructure
The acquisition complements Gilead’s existing oncology expertise and development infrastructure
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
The new device promises faster, more efficient cardiac procedures while maintaining the safety and effectiveness clinicians expect
Biopharma companies face persistent hurdles in cell line development, including long timelines, low yields, and high failure rates for novel molecules
Chronic GVHD is a serious and potentially life-threatening condition, imposing profound physical and emotional burdens on a substantial proportion of patients following allogeneic stem cell transplantation
Cyble’s 2026 healthcare threat report flags a sharp rise in Asia-focused ransomware, with hospitals, elderly care, and diagnostic systems increasingly in cybercriminal crosshairs
API maker begins circulation of second and final call money notice for partly paid-up rights shares, completing the last leg of its 2024 fundraising cycle
The India FMCG business showed a sequential recovery and is expected to post high-single digit growth
The partnership aims to accelerate clinical trial timelines, boost data quality, and improve decision-making for sponsors worldwide
Subscribe To Our Newsletter & Stay Updated
